Physician profile
Dev Gandhi
NPI 1124656665
$1,569.57
in general payments reported to CMS, 2019-2025
15 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.44 · 2021: $55.77 · 2022: $25.92 · 2024: $237 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $336.62 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $288.40 | 2024-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $207.75 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $190.77 | 2024-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $137.50 | 2024-2025 | |
| Corium, LLC | $107.18 | 2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $85.35 | 2025 | Qelbree |
| Lundbeck LLC | $59.94 | 2025 | Abilify Asimtufii, Rexulti |
| Mallinckrodt Hospital Products INC. | $43.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.97 | 2025 | Spravato |
| Novo Nordisk INC | $18.44 | 2020 | |
| Neurocrine Biosciences, INC. | $17.50 | 2024 | Ingrezza |
| Neos Therapeutics, LP | $14.46 | 2025 | Exxua |
| Merck Sharp & Dohme LLC | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dev Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.